-
Mashup Score: 21
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 18An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL - 2 month(s) ago
Prinz et al. present an “AND” switch CAR T cell construct that fully activates only when it binds to CD19 and CD80/CD86 found on lymphoma cells. Compared with CAR T cells targeting only CD19, they reveal improved anti-tumor activity while sparing healthy CD19-expressing cells, like non-malignant B cells and metaneural pericytes.
Source: www.cell.comCategories: General Medicine News, Hematologists1Tweet-
Congratulations to Lars Fabian Prinz, Markus Chmielewski & coauthors: An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL: Cell Rep Med https://t.co/efKCxE94mk #lymsm support by @dfg_public #SFB1530 & @Krebshilfe_Bonn https://t.co/kPpnppFzYR
-
-
Mashup Score: 14
Objective Preventing severe COVID-19 remains a priority globally, particularly in the immunocompromised population. As shown in healthy individuals, immunity against SARS-CoV-2 can be yielded by pre…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hematologists1Tweet-
Just out online, by Sibylle Mellinghoff et al.: Hybrid immunity to SARS‐CoV‐2 in patients with chronic lymphocytic leukemia. Eur. J. of Haematol. https://t.co/ZF8vgG0Kqc #CLL #Coronavirus #Vaccine #Immunity @UKKoeln @UniCologne https://t.co/wUHrImAneB
-
-
Mashup Score: 28Redaktion live: Kölner Onkologe Michael Hallek spricht über Erfolge in der Krebsforschung - 3 month(s) ago
Der international renommierte Mediziner spricht im Forum Volkshochschule am Neumarkt über seine Arbeit im Kampf gegen Krebs.
Source: www.ksta.deCategories: General Medicine News, Hematologists1Tweet-
Freue mich sehr auf das Gespräch. https://t.co/Hku7MdOGVx
-
-
Mashup Score: 3
Nature Medicine – In a large single-arm phase 2 trial, the anti-PD-1 inhibitor tislelizumab combined with the next-generation BTK inhibitor zanubrutinib had an overall response rate of 58.3% and…
Source: www.nature.comCategories: General Medicine News, Hematologists1Tweet-
RT @tobyeyre82: @Othman_Al_Sawaf et al RT1 trial now in nature medicine #ASH23 #RT https://t.co/0a4L1Ml0yF
-
-
Mashup Score: 22
Drug-resistant Pseudomonas aeruginosa poses an emerging threat to human health with an urgent need for alternative therapeutic approaches. Elucidation of the human immune response to the P. aeruginosa type 3 secretion system reveals highly potent T3SS-neutralizing antibodies with antibiotic-like activity in vivo.
Source: www.cell.comCategories: General Medicine News, Hematologists1Tweet-
Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa. Congratulations to Alexander Simonis and Jan Rybniker, & all coauthors, Dept I Int Med, @UKKoeln @UniCologne @DZIF_ Just online in Cell https://t.co/sOZIgz7nBI
-
-
Mashup Score: 0Datenbremsen im Gesundheitswesen lösen - 7 month(s) ago
Deutschland gilt als Entwicklungsland bei der Digitalisierung des Gesundheitswesens. Zum Wohle der Patienten sollten Daten intelligenter genutzt werden als bisher. Ein Gastbeitrag
Source: www.faz.netCategories: Hematologists1, Latest HeadlinesTweet-
Datenbremsen im Gesundheitswesen lösen. Guter Beitrag von Jürgen Kühling und Roman Schildbach zu den aktuellen Gesetzesvorhaben der Bundesregierung. @BMG_Bund https://t.co/9f7sdJqS7p
-
-
Mashup Score: 2Home - 7 month(s) ago
Die Stiftung Kölner Krebsforschung ist eine Initiative Kölner Bürgerinnen und Bürger, die unter dem Motto „Exzellenz initiieren“ den Krebsforschungsstandort Köln stärken möchten. Ziel der Stiftung ist es, in Köln eine Infrastruktur und ein gutes Forschungsklima für Nachwuchswissenschaftler zu schaffen.
Source: exzellenz-initiieren.deCategories: Hematologists1, Latest HeadlinesTweet-
RT @peltzer_lab: Thanks for supporting our science https://t.co/mHeTyhNvGl @HallekMichael @SFB1530 @UniCologne #CLL #lymphoma
-
-
Mashup Score: 42nd How I Manage: CAR-T Therapies and Bispecific Antibodies for my patients | ESH - European School of Haematology - 7 month(s) ago
Chairs : Ulrich Jäger, Marie José Kersten, Loretta Nastoupil September 29-October 1, 2023 – Berlin, Germany Chairs: Ulrich J ä ger, Marie Jos é Kersten, Loretta Nastoupil CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies. The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available thera pies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on
Source: www.esh.orgCategories: Latest Headlines, Oncologists2Tweet-
RT @ESHaematology: 🙌 #ESHCART2023 STARTS THIS FRIDAY! Registration is still open ➡️ https://t.co/vt5VCXEzAL We are looking forward to welco…
-
-
Mashup Score: 27th Translational Research Conference: Lymphoid Malignancies | ESH - European School of Haematology - 7 month(s) ago
Chairs : Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt 7th Translational Research Conference Lymphoid Malignancies October 20-22, 2023 – Estoril, Portugal Chairs: Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt ESH Translational Research Conferences focus on leading-edge basic, clinical and therapeutic research and future perspectives. The presentation of unpublished data is encouraged. This leading-edge translational research conference will address the rapidly evolving field of lymphoid
Source: www.esh.orgCategories: Hematologists1, Latest HeadlinesTweet-
RT @ESHaematology: ⌛️ #ESHLYMPHOID2023 STARTS IN 1 MONTH! Don't delay: REGISTER NOW & join us soon in Estoril 🇵🇹 ➡ https://t.co/H7msA3tCdI…
-
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a phase II trial. Cramer et al., Am Hematol 2024, online. #CLL #leusm #GCLLSG #leukemia @UKKoeln @UniCologne https://t.co/T1vEM2YqQg https://t.co/78Z1srEG0Q